|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%).
|
30292978 |
2018 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
|
19554337 |
2009 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 sequencing and loss of heterozygosity analysis was performed for 15 surgery samples of astrocytoma and early and late passages of cells derived from those and for 11 archival samples.
|
21326241 |
2011 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations were associated with prolonged overall survival in the whole series of patients exclusive of pilocytic astrocytoma (P<0.001), WHO grade Ⅱ patients who received no adjuvant therapy after surgery (P=0.014) and WHO grade Ⅲ patients who received concomitant chemoradiotherapy (standard schedule) after surgery (P=0.033).
|
21874255 |
2011 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations occurred frequently in low grades of astrocytoma.
|
22772731 |
2012 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As the presence of the p.R132H mutation in the IDH1 gene seems to be a more powerful prognostic marker than O(6)-methylguanine-DNA methyltransferase promoter status, we evaluated the presence of IDH1 mutation in Polish patients with astrocytoma, glioblastoma, oligoastrocytoma, ganglioglioma, oligodendroglioma, and ependymoma.
|
23934769 |
2014 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both 3D pCASL and DWI could be useful tools for distinguishing low- from high-grade diffuse gliomas and have the potential to differentiate different IDH1 mutation statuses of astrocytoma.
|
29777252 |
2018 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Copy number variation (CNV) abundance associated with survival in low-grade and IDH mutant astrocytoma has been reported.
|
31134296 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CXCR7 was overexpressed in astrocytoma and correlates with CXCR4 and IDH1 in AGII and CXCR4, IDH1 and HIF1α in GBM.
|
24970694 |
2015 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP.
|
28327577 |
2017 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
False positive mismatch sign was noted in 28.5% (12/42) Group O tumors, but none of the tumors in Group G. A combination of all three factors: age under 40 years at first diagnosis, a tumor size larger than 6 cm and T2-FLAIR mismatch was highly specific for IDH mutant astrocytoma (Group A).
|
30536195 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, later genome-wide methylation profiling of the diagnostic tumor undertaken to guide treatment, revealed characteristics most consistent with IDH-mutant astrocytoma.
|
28993028 |
2018 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
|
27460417 |
2016 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, the mutation load was similar, as was the methylation pattern, being consistent with IDH-mutant astrocytoma.
|
29741737 |
2018 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation.
|
24335697 |
2014 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004).
|
25797251 |
2015 |
|
Childhood Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the status of p53, IDH1/2, and chromosome 7 to determine the most useful panel to distinguish astrocytoma from astrocytosis.
|
21343879 |
2011 |
|
Childhood Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, the results from immunohistochemistry and DNA sequencing showed that, compared with primary astrocytoma, there was no change of IDH1 status in recurrent astrocytoma whatever tumour pathological grade raise or indolent.
|
28928859 |
2017 |
|
Childhood Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Median OS was similar for IDH1/2wt astrocytoma WHO IV patients (23.8 months) and IDH1/2wt glioblastoma patients (19.2 months) (Cox proportional hazard model: hazard ratio (HR) 1.27, 95% confidence interval (CI) 0.85-1.88, p=0.242).
|
31637414 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we found two genetic/clinical correlations that must be evaluated to understand their impact in the clinical setting: i) how is PTEN deletion a favorable prognostic factor in GBM IDH wildtype and an unfavorable prognostic factor in astrocytoma IDH wildtype and ii) how EGFR amplification is an independent and strong factor of response to radiotherapy.
|
31623593 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis further revealed that prognosis of astrocytoma was significantly associated with Sp1 expression (p = 0.036) and IDH-1 expression (p < 0.001).
|
29948615 |
2019 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients.
|
30071292 |
2018 |
|
Childhood Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |